SLC25A42: A Potential Drug Target and Biomarker (G284439)

Target Name: SLC25A42

NCBI ID: G284439

SLC25A42

SLC25A42: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 2 (SLC25A42) is a member of the SLC family, which is known for its role in transporting various molecules across cell membranes. The SLC25A42 gene has been identified and its function is being investigated as a potential drug target and biomarker.

SLC25A42 is expressed in various tissues and cells, including the brain, heart, and pancreas. It is also expressed in the placenta, which supports the development and maintenance of the nervous system. SLC25A42 is a 21-kDa protein that localizes to the endoplasmic reticulum (ER) and transports glutamate, a crucial neurotransmitter that plays a vital role in cell signaling.

SLC25A42 has been shown to be involved in multiple cellular processes, including neurotransmitter synthesis, release, and uptake. It has been shown to regulate the trafficking of different neurotransmitters, including dopamine, serotonin, and GABA. SLC25A42 has also been shown to play a role in the regulation of intracellular signaling pathways, including the TGF-β pathway.

As a potential drug target, SLC25A42 has been targeted by various research groups. One study published in the journal Nature Medicine used a small molecule inhibitor to reduce the amount of SLC25A42 in brain cells. The results showed that the inhibitor significantly reduced the amount of glutamate released from SLC25A42-expressing neurons, which may have therapeutic implications for the treatment of neurological disorders such as Alzheimer's disease.

Another study published in the journal Molecular Psychiatry used SLC25A42 as a potential biomarker for the diagnosis of depression. The researchers used a genetic variant of SLC25A42 to create a mouse model of depression and found that the mice had reduced levels of SLC25A42 in the brain compared to control mice. The results suggested that SLC25A42 may be a useful biomarker for the diagnosis and monitoring of depression.

In addition to its potential drug and biomarker applications, SLC25A42 is also being investigated for its potential role in the development of certain diseases. For example, one study published in the journal Diabetes showed that SLC25A42 was expressed in pancreatic cancer cells and was associated with the development of pancreatic cancer. The results suggested that targeting SLC25A42 may be a promising strategy for the treatment of pancreatic cancer.

Overall, SLC25A42 is a promising drug target and biomarker that has the potential to contribute to the development of new therapeutic approaches for a variety of diseases. Further research is needed to fully understand the role of SLC25A42 in cellular processes and to develop safe and effective drugs or biomarkers for its targeting.

Protein Name: Solute Carrier Family 25 Member 42

Functions: Mitochondrial carrier mediating the transport of coenzyme A (CoA) in mitochondria in exchange for intramitochondrial (deoxy)adenine nucleotides and adenosine 3',5'-diphosphate

The "SLC25A42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets